The magnitude and sustainability of treatment benefit of zuranolone on function and well-being as assessed by the SF-36 in adult patients with MDD and PPD: An integrated analysis of 4 randomized clinical trials

Anita H. Clayton, Ellison Suthoff, Rakesh Jain, Mark Kosinski, Moshe Fridman, Kristina M. Deligiannidis, Samantha Meltzer-Brody, Shih-Yin Chen, Leon Gervitz, Ming-Yi Huang, Madhukar Trivedi, Vijayveer Bonthapally

Open source

DOI: 10.1016/j.jad.2024.01.268
Published: 2024-04
Container: Journal of Affective Disorders
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.jad.2024.01.268,
  title = {The magnitude and sustainability of treatment benefit of zuranolone on function and well-being as assessed by the SF-36 in adult patients with MDD and PPD: An integrated analysis of 4 randomized clinical trials},
  author = {Anita H. Clayton and Ellison Suthoff and Rakesh Jain and Mark Kosinski and Moshe Fridman and Kristina M. Deligiannidis and Samantha Meltzer-Brody and Shih-Yin Chen and Leon Gervitz and Ming-Yi Huang and Madhukar Trivedi and Vijayveer Bonthapally},
  year = {2024},
  journal = {Journal of Affective Disorders},
  doi = {10.1016/j.jad.2024.01.268},
  url = {https://doi.org/10.1016/j.jad.2024.01.268}
}

RIS

TY  - JOUR
TI  - The magnitude and sustainability of treatment benefit of zuranolone on function and well-being as assessed by the SF-36 in adult patients with MDD and PPD: An integrated analysis of 4 randomized clinical trials
AU  - Anita H. Clayton
AU  - Ellison Suthoff
AU  - Rakesh Jain
AU  - Mark Kosinski
AU  - Moshe Fridman
AU  - Kristina M. Deligiannidis
AU  - Samantha Meltzer-Brody
AU  - Shih-Yin Chen
AU  - Leon Gervitz
AU  - Ming-Yi Huang
AU  - Madhukar Trivedi
AU  - Vijayveer Bonthapally
PY  - 2024
JO  - Journal of Affective Disorders
DO  - 10.1016/j.jad.2024.01.268
UR  - https://doi.org/10.1016/j.jad.2024.01.268
ER  -

APA

Clayton, A. H., Suthoff, E., Jain, R., Kosinski, M., Fridman, M., Deligiannidis, K. M., Meltzer-Brody, S., Chen, S., Gervitz, L., Huang, M., Trivedi, M., & Bonthapally, V. (2024). The magnitude and sustainability of treatment benefit of zuranolone on function and well-being as assessed by the SF-36 in adult patients with MDD and PPD: An integrated analysis of 4 randomized clinical trials. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2024.01.268

Source records

crossref · retrieved 2026-09-26T14:08:52.878Z